Advertisement

Metabolic Brain Disease

, Volume 34, Issue 1, pp 173–181 | Cite as

Neuroprotective effects of matrine on scopolamine-induced amnesia via inhibition of AChE/BuChE and oxidative stress

  • Kaiyue SunEmail author
  • Yuting Bai
  • Rong Zhao
  • Zijiao Guo
  • Xiang Su
  • Peiqi Li
  • Pengyu Yang
Original Article
  • 68 Downloads

Abstract

The present study was designed to evaluate the effects of matrine (MAT) on scopolamine (SCOP)-induced learning and memory impairment. After successive oral administration of MAT to mice for three days at doses of 0.4, 2, and 10 mg/kg, we assessed improvements in learning and memory and investigated the mechanism of action of SCOP-induced amnesia. Donepezil at a dose of 3 mg/kg was used as a standard memory enhancer. MAT significantly improved SCOP-induced learning and memory impairment in novel object recognition and Y-maze tests at doses of 0.4, 2, and 10 mg/kg. Furthermore, MAT inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and decreased oxidative stress in the brain, as evidenced by increased total antioxidant capacity, total superoxide dismutase levels, and catalase activities as well as decreased malondialdehyde levels. Additionally, there was a significant negative correlation between the percentage of spontaneous alternation in the Y maze and AChE activity in the cortex and hippocampus. MAT ameliorated SCOP-induced amnesia by the inhibition of both AChE/BuChE activities and oxidative stress. This study provides further evidence to encourage the development of MAT as a drug for the prevention or treatment of Alzheimer’s disease.

Keywords

Matrine Cholinesterase Anti-oxidative stress Learning and memory Alzheimer’s disease 

Abbreviations

amyloid-β

AChE

acetylcholinesterase

Ach

acetylcholine

AD

Alzheimer’s disease

BuChE

butyrylcholinesterase

CAT

catalase

ChE

cholinesterase

DON

donepezil

MAT

matrine

MDA

malondialdehyde

NOR

novel object recognition

Nrf2

nuclear factor-E2 related factor-2

SCOP

scopolamine

T-AOC

total anti-oxidantant capacity

T-SOD

total superoxide dismutase

Notes

Acknowledgements

This work was supported by the grant from Shanxi Agricultural University Science and Technology Innovation Fund (2014YJ04), China.

Compliance with ethical standards

Ethical approval

Animals’ use and disposal had been approved by the animal ethics committee of Shanxi Agricultural University.

Conflict of interest

The authors declare no competing financial interest.

References

  1. Alvarez-Jimenez R, Groeneveld GJ, van Gerven JM, Goulooze SC, Baakman AC, Hay JL, Stevens J (2016) Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. Br J Clin Pharmacol 82:1011–1021CrossRefGoogle Scholar
  2. Alzheimer's Association (2016) 2016 Alzheimer's disease facts and figures. Alzheimers Dement 12:459–509CrossRefGoogle Scholar
  3. Antunes M, Biala G (2012) The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 13:93–110Google Scholar
  4. Araujo JA, Studzinski CM, Milgram NW (2005) Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Neuro-Psychopharmacol Biol Psychiatry 29:411–422CrossRefGoogle Scholar
  5. Banks WA (2012) Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev 64:629–639CrossRefGoogle Scholar
  6. Bartus RT, Dean RL, Ljubic B, Lippa A (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414CrossRefGoogle Scholar
  7. Ben-Barak J, Dudai Y (1980) Scopolamine induces an increase in muscarinic receptor level in rat hippocampus. Brain Res 193:309–313CrossRefGoogle Scholar
  8. Botton PH, Costa MS, Ardais AP, Mioranzza S, Souza DO, da Rocha JB, Porciúncula LO (2010) Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. Behav Brain Res 214:254–259CrossRefGoogle Scholar
  9. Chen JX, Shen HH, Niu M, Guo YM, Liu XQ, Han YZ, Zhang YM, Zhao YL, Bai BK, Zhou WJ, Xiao XH (2016) Anti-hepatitis B virus effect of matrine-type alkaloid and involvement of p38 mitogen-activated protein kinase and tumor necrosis factor receptor-associated factor 6. Virus Res 215:104–113CrossRefGoogle Scholar
  10. Cui LL, Cai YJ, Cheng WW, Liu G, Zhao JG, Cao H, Tao H, Wang Y, Yin MK, Liu TT, Liu Y, Huang PR, Liu Z, Li KS, Zhao B (2017) A novel, multi-target natural drug candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis. Mol Neurobiol 54:1939–1952CrossRefGoogle Scholar
  11. Darvesh S (2013) Butyrylcholinesterase radioligands to image Alzheimer's disease brain. Chem Biol Interact 203:354–357CrossRefGoogle Scholar
  12. Dighe SN, Deora GS, DelaMora E, Nachon F, Chan S, Parat MO, Brazzolotto X, Ross BP (2016) Discovery and structure-activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening. J Med Chem 59:7683–7689CrossRefGoogle Scholar
  13. Espada S, Rojo AI, Salinas M, Cuadrado A (2009) The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK-3beta: connecting neuro transmission with neuroprotection. J Neurochem 110:1107–1119CrossRefGoogle Scholar
  14. Fodale V, Quattrone D, Trecroci C, Caminiti V, Santamaria LB (2006) Alzheimer's disease and anaesthesia: implications for the central cholinergic system. Br J Anaesth 97:445–452CrossRefGoogle Scholar
  15. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR (2002) Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm (Vienna) 109:1053–1065CrossRefGoogle Scholar
  16. Haider S, Batool Z, Ahmad S, Siddiqui RA, Haleem DJ (2018) Walnut supplementation reverses the scopolamine-induced memory impairment by restoration of cholinergic function via mitigating oxidative stress in rats: a potential therapeutic intervention for age related neurodegenerative disorders. Metab Brain Dis 33:39–51CrossRefGoogle Scholar
  17. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Greig NH, Klein J (2007) Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem 100:1421–1429CrossRefGoogle Scholar
  18. Inestrosa NC, Dinamarca MC, Alvarez A (2008) Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J 275:625–632CrossRefGoogle Scholar
  19. Ladner CJ, Lee JM (1998) Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 57:719–731CrossRefGoogle Scholar
  20. Li HJ, Li XJ, Bai ML, Suo YE, Zhang GH, Cao XY (2015) Matrine inhibited proliferation and increased apoptosis in human breast cancer MCF-7 cells via upregulation of Bax and downregulation of Bcl-2. Int J Clin Exp Pathol 8:14793–14799PubMedPubMedCentralGoogle Scholar
  21. Li J, Gao L, Sun K, Xiao D, Li W, Xiang L, Qi J (2016) Benzoate fraction from Gentiana rigescens Franch alleviates scopolamine-induced impaired memory in mice model in vivo. J Ethnopharmacol 193:107–116CrossRefGoogle Scholar
  22. Liu X, Zhang X, Ma K, Zhang R, Hou P, Sun B, Yuan S, Wang Z, Liu Z (2016) Matrine alleviates early brain injury after experimental subarachnoid hemorrhage in rats: possible involvement of PI3K/Akt-mediated NF-κB inhibition and Keap1/Nrf2-dependent HO-1 induction. Cell Mol Biol (Noisy-le-grand) 62:38–44CrossRefGoogle Scholar
  23. Liu W, Rabinovich A, Nash Y, Frenke D, WangY YMBH, Weinreb O (2017) Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells. Neuropharmacology 113:445–456CrossRefGoogle Scholar
  24. Lleó A, Greenberg SM, Growdon JH (2006) Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 57:513–533CrossRefGoogle Scholar
  25. López N, Tormo C, Blas ID, Llinares I, Alom J (2013) Oxidative stress in Alzheimer’s disease and mild cognitive impairment with high sensitivity and specificity. J Alzheimers Dis 33:823–829CrossRefGoogle Scholar
  26. Luque-Contreras D, Carvaja K, Toral-Rios D, Franco-Bocanegra D, Campos-Peña V (2014) Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer's disease? Oxidative Med Cell Longev 2014:497802CrossRefGoogle Scholar
  27. Meng F, Wang J, Ding F, Xie Y, Zhang Y, Zhu J (2017) Neuroprotective effect of matrine on MPTP-induced Parkinson's disease and on Nrf2 expression. Oncol Lett 13:296–300CrossRefGoogle Scholar
  28. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O (2002a) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110:627–639CrossRefGoogle Scholar
  29. Mesulam M, Guillozet A, Shaw P, Quinn B (2002b) Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 9:88–93CrossRefGoogle Scholar
  30. Milić M, Timić T, Joksimović S, Biawat P, Rallapalli S, Divljaković J, Radulović T, Cook JM, Savić MM (2013) PWZ-029, an inverse agonist selective for α5 GABAA receptors, improves object recognition, but not water-maze memory in normal and scopolamine-treated rats. Behav Brain Res 241:206–213CrossRefGoogle Scholar
  31. Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J (2009) Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase deficient mice. J Pharm Pharm Sci 12:79–85CrossRefGoogle Scholar
  32. Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4:273–277CrossRefGoogle Scholar
  33. Qu Z, Zhang JZ, Yang HG, Gao J, Chen H, Liu CX, Gao WY (2017) Prunella vulgaris L, an edible and medicinal plant, attenuates scopolamine-induced memory impairment in rats. J Agric Food Chem 65:291–300CrossRefGoogle Scholar
  34. Russ TC, Morling JR (2012) Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 9:CD009132Google Scholar
  35. Sarter M, Bodewitz G, Stephens DN (1988) Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology 94:491–495CrossRefGoogle Scholar
  36. Schroeter H, Williams RJ, Matin R, Iversen L, Rice-Evans CA (2000) Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. Free Radic Biol Med 29:1222–1233CrossRefGoogle Scholar
  37. Venkatesan R, Subedi L, Yeo EJ, Kim SY (2016) Lactucopicrin ameliorates oxidative stress mediated by scopolamine-induced neurotoxicitythroughactivationof the NRF2 pathway. Neurochem Int 99:133–146CrossRefGoogle Scholar
  38. Xiao J, Li SY, Sui Y, Wu Q, Li XP, Xie BJ, Zhang MW, Sun ZD, Cui RJ (2014) Lactobacillus casei-01 facilitates the ameliorative effects of Proanthocyanidins extracted from Lotus seedpod on learning and memory impairment in scopolamine-induced amnesia mice. PLoS One 9:e112773CrossRefGoogle Scholar
  39. Xu QQ, Xu YJ, Yang C, Tang Y, Li L, Cai HB, Hou BN, Chen HF, Wang Q, Shi XG, Zhang SJ (2016) Sodium Tanshinone IIA sulfonate attenuates scopolamine-induced cognitive dysfunctions via improving cholinergic system. Biomed Res Int 2016:9852536PubMedPubMedCentralGoogle Scholar
  40. Yin LL, Zhu XZ (2005) The involvement of central cholinergic system in (+)-matrine-induced antinociception in mice. Pharmacol Biochem Behav 80:419–425CrossRefGoogle Scholar
  41. Yue W, Li Y, Zhang T, Jiang M, Qian Y, Zhang M, Sheng N, Feng S, Tang K, Yu X, Shu Y, Yue C, Jing N (2015) ESC-derived basal forebrain cholinergic neurons ameliorate the cognitive symptoms associated with Alzheimer's disease in mouse models. Stem Cell Reports 5:776–790CrossRefGoogle Scholar
  42. Zhao P, Zhou R, Zhu XY, Hao YJ, Li N, Wang J, Niu Y, Sun T, Li YX, Yu JQ (2015) Matrine attenuates focal cerebral ischemic injury by improving antioxidant activity and inhibiting apoptosis in mice. Int J Mol Med 36:633–644CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of Animal Science and Veterinary MedicineShanxi Agricultural UniversityTaiguPeople’s Republic of China

Personalised recommendations